Article
Oncology
Chun-Yen Yu, Po-Hsun Huang, Leo Leung-Chit Tsang, Hsien-Wen Hsu, Wei-Xiong Lim, Ching-Chun Weng, Tung-Liang Huang, Chien-Chin Hsu, Chao-Long Chen, Hsin-You Ou, Yu-Fan Cheng
Summary: This study aimed to evaluate the safety and efficacy of Yttrium-90 radioembolization in unresectable hepatocellular carcinoma. The results showed that Yttrium-90 radioembolization effectively controlled hepatocellular carcinoma, especially in advanced cases. Patients successfully bridging to surgical resection or transplantation had excellent overall survival.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ammar Sarwar, Alexei Kudla, Jeffrey L. Weinstein, Aamir Ali, Raza Malik, Andrea Bullock, Khalid O. Khwaja, Michael Curry, Salomao Faintuch, Muneeb Ahmed
Summary: This study reviewed the technical feasibility of resin microsphere yttrium-90 radioembolization using the MIRD model and found that prescribed activity calculated by MIRD was significantly higher than BSA model. The results indicated that MIRD prescribed activity with target absorbed doses up to 200 Gy can be successfully administered without prophylactic embolization in selected patients.
EUROPEAN RADIOLOGY
(2021)
Article
Medicine, General & Internal
Nur Sener, Abdullah Yakupoglu
Summary: This retrospective study analyzed the outcomes of combining yttrium-90 transarterial radioembolization with capecitabine chemotherapy in 22 patients with hepatocellular carcinoma and portal vein involvement. The results showed that the combined treatment was effective in controlling disease progression and improving survival rates.
Article
Radiology, Nuclear Medicine & Medical Imaging
Marnix Lam, Etienne Garin, Marco Maccauro, S. Cheenu Kappadath, Daniel Y. Sze, Cuneyt Turkmen, Murat Cantasdemir, Paul Haste, Ken Herrmann, Hamad Saleh Alsuhaibani, Matthew Dreher, Kirk D. Fowers, Riad Salem
Summary: This study aimed to investigate the relationship between tumor absorbed dose and clinical outcomes in hepatocellular carcinoma patients. The results showed a significant association between absorbed dose and objective response, overall survival, and alpha fetoprotein response.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Review
Gastroenterology & Hepatology
Ahmad Hamad, Hassan Aziz, Ihab R. Kamel, Dayssy Alexandra Diaz, Timothy M. Pawlik
Summary: Radioembolization (RE) with 90Yttrium (Y90) has shown promising results for patients with HCC, regardless of stage. It can be used as a downstaging treatment for advanced HCC patients and has comparable outcomes to other standard treatments. Radiation lobectomy (RL) can be used to treat the liver lobe with HCC and induce compensatory hypertrophy of the future liver remnant (FLR).
JOURNAL OF GASTROINTESTINAL SURGERY
(2023)
Article
Gastroenterology & Hepatology
Ajalaya Teyateeti, Armeen Mahvash, James Long, Mohamed Abdelsalam, Rony Avritscher, Ahmed Kaseb, Bruno Odisio, Gregory Ravizzini, Devaki Surasi, Achiraya Teyateeti, Homer Macapinlac, Srinivas Cheenu Kappadath
Summary: TARE with/without sorafenib based on individuals' disease burden achieved a disease control rate of approximately 70%, with intrahepatic progression being the dominant failure pattern. Extrahepatic progression was more common in procedures with initially high disease burden.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Willie Luedemann, Johannes Kahn, Daniel Pustelnik, Juliane Hardt, Georg Boening, Martin Jonczyk, Holger Amthauer, Bernhard Gebauer, Bernd Hamm, Gero Wieners
Summary: This study aims to characterize potential responders of Y-90 radioembolization through analysis of clinical variables and MRI tumor volumetry. Pre-treatment baseline MRI can be used to identify promising candidates for Y-90 radioembolization and adjust therapeutic regimens early on.
EUROPEAN RADIOLOGY
(2022)
Article
Optics
Jina Shim, Gyoung Min Kim, Do Young Kim, Mi Jin Yun, Soo Hyun Seo, Jong Yun Won, Youngjin Lee
Summary: The study measured and evaluated the radiation exposure of radiation operators during yttrium-90 radioembolization treatment for hepatocellular carcinoma patients. The results showed that the radiation exposure to the administering operator was within the safe exposure range, indicating that it can be controlled within an acceptable range.
Article
Radiology, Nuclear Medicine & Medical Imaging
Andrew C. Gordon, Sarah B. White, Vanessa L. Gates, Daniel Procissi, Kathleen R. Harris, Yihe Yang, Zhuoli Zhang, Weiguo Li, Tianchu Lyu, Xiaoke Huang, Reed A. Omary, Riad Salem, Robert J. Lewandowski, Andrew C. Larson
Summary: The study used MRI to evaluate changes in tumor hypoxia after Y-90 radioembolization, finding that Y90 treatment may influence tumor oxygenation and that Delta R2* could be a predictive imaging biomarker for tumor response and treatment.
ACADEMIC RADIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Riad Salem, Guy E. Johnson, Edward Kim, Ahsun Riaz, Vivian Bishay, Eveline Boucher, Kirk Fowers, Robert Lewandowski, Siddharth A. Padia
Summary: The LEGACY study evaluated the efficacy of yttrium-90 glass microspheres in treating solitary, unresectable HCC <= 8 cm, showing promising response rates and durable responses in a multicenter setting.
Article
Gastroenterology & Hepatology
Ahmed Gabr, Laura Kulik, Samdeep Mouli, Ahsun Riaz, Rehan Ali, Kush Desai, Ronald A. Mora, Daniel Ganger, Haripriya Maddur, Steven Flamm, Justin Boike, Christopher Moore, Bartley Thornburg, Ali Alasadi, Talia Baker, Daniel Borja-Cacho, Nitin Katariya, Daniela P. Ladner, Juan Carlos Caicedo, Robert J. Lewandowski, Riad Salem
Summary: This study presents the long-term outcomes of liver transplantation for HCC patients bridged or downstaged by Y90, demonstrating the effectiveness of Y90 in HCC treatment and the benefit of achieving extensive or complete necrosis for improved recurrence-free survival.
Review
Multidisciplinary Sciences
Simon Lemieux, Alex Buies, Alexis F. Turgeon, Julie Hallet, Gaetan Daigle, Francois Cote, Steeve Provencher
Summary: Yttrium-90 transarterial radioembolization did not show significant effects on survival, progression-free survival, time to progression, disease control rate, and incidence of gastro-intestinal ulcers in non-surgical HCC patients, but was associated with significantly lower rates of grade >= 3 adverse events. Further randomized controlled trials are needed to determine optimal treatment.
Article
Oncology
Cynthia De la Garza-Ramos, Cameron J. Overfield, S. Ali Montazeri, Harris Liou, Ricardo Paz-Fumagalli, Gregory T. Frey, J. Mark McKinney, Charles A. Ritchie, Zlatko Devcic, Andrew R. Lewis, Denise M. Harnois, Tushar Patel, Beau B. Toskich
Summary: This study found that for patients with ALBI grade 2 and CP-B liver function, treating less than 14.5% of the liver is less likely to result in grade/class increases. However, there was no definitive threshold found for biochemical toxicity in ALBI grade 1 and CP-A patients within the scope of this study.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Cardiac & Cardiovascular Systems
Phillip L. Guichet, Bedros Taslakian, Chenyang Zhan, Eric Aaltonen, Sean Farquharson, Ryan Hickey, Cash J. Horn, Jonathan S. Gross
Summary: This study found that sarcopenia was associated with increased 180-day and 1-year mortality in patients with hepatocellular carcinoma undergoing Y-90 radioembolization. Sarcopenia was also identified as an independent predictor of survival, particularly for patients with BCLC stage B disease.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Do Young Kim, Hye Won Lee, Wonseok Kang, Gyoung Min Kim, Jong Yun Won, Mijin Yun
Summary: The study investigated the predictive role of F-18-fluorodeoxyglucose PET/CT in HCC patients undergoing Y-90 transarterial radioembolization. The cutoff of TLR did not impact disease control rate and survival, suggesting further studies with larger sample sizes are needed.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
